Genetic screening identifies glial adenosine as a therapeutic target in alpha-synucleinopathy

Parkinson's disease and related conditions like dementia with Lewy bodies belong to a group of disorders where a specific protein, called alpha-synuclein, clumps together inside nerve cells. These clumps disrupt how the brain works, leading to tremors, stiffness, and memory loss. For decades, scientists have focused their efforts on fixing the nerve cells themselves, hoping to stop the protein from misfolding or to clear the debris it leaves behind. Yet, despite this intense focus, there are still no treatments that can slow down or stop the disease from progressing. A growing body of research suggests that the problem might not be limited to the nerve cells alone. The brain is filled with support cells called glia, which act as a maintenance crew for the nervous system, managing waste, providing nutrients, and keeping the environment stable. If these support cells are failing to do their job, or if they are actively contributing to the trouble, then targeting them could offer a new path forward for patients who currently have no disease-modifying options.

In a recent study, researchers turned to a tiny fruit fly to explore this possibility, building a living model that could test how different genes in support cells affect the disease. They engineered these flies so that their nerve cells produced human alpha-synuclein, causing the same kind of damage seen in people with Parkinson's. The flies quickly developed symptoms, including trouble moving and the loss of nerve cells. The researchers then set out to find a way to fix this by looking at the support cells, or glia, that surround the sick nerve cells. They systematically turned off, or knocked down, every single gene in the fly's genome that is known to make enzymes involved in chemical signaling, one by one, specifically within the glia. This massive search, known as a forward genetic screen, allowed them to see which specific genetic changes in the support cells could rescue the dying nerve cells and restore movement.

The search yielded a clear and surprising pattern. Among the thousands of genes tested, five specific genes stood out as the most effective at stopping the disease. These genes are all involved in how the body handles a molecule called adenosine, which acts as a chemical signal in the brain. When the researchers reduced the activity of any one of these five genes in the glia, the level of adenosine in the brain went up. This increase was not just a side effect; it was the key to the cure. The flies with higher adenosine levels showed dramatic improvements. They moved better, their nerve cells stopped dying, and the harmful clumps of alpha-synuclein that had been building up in their brains were reduced. The study confirmed that the support cells were the source of this benefit, as the changes happened only when the genes were altered in the glia, not in the nerve cells themselves.

To understand exactly how this worked, the researchers traced the path of the signal. They found that the extra adenosine produced by the support cells did not work by acting on the support cells themselves. Instead, it traveled to the nerve cells and bound to a specific receiver on their surface, known as the adenosine receptor. When this receptor was activated, it triggered a chain of events that protected the nerve cell and reduced the toxic protein. If the researchers blocked this receptor, the benefits vanished, proving that the communication between the support cells and the nerve cells was essential. The findings suggest that boosting adenosine levels through the support cells, rather than the nerve cells, could be a powerful way to treat alpha-synucleinopathies. While this work was done in flies, it points to a specific and previously overlooked mechanism in the brain, offering a concrete new target for developing therapies that could one day change the course of Parkinson's disease and related conditions.